Correlation between PSMA and VEGF expression as markers for LNCaP tumor angiogenesis

Journal of Biomedicine and Biotechnology

Volumn 2005, Issue 3, 2005, Pages 287-290

  Tsui, Paulus ^a   Rubenstein, Marvin ^a,b   Guinan, Patrick ^a,b,c  

^a Hektoen Institute for Medical Research   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; EPIDERMAL GROWTH FACTOR; PACLITAXEL; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RECEPTOR PROTEIN; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; CANCER CONTROL; CELL SURFACE; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIUM; HUMAN; HUMAN CELL; IMMUNOHISTOLOGY; METASTASIS; MOUSE; NONHUMAN; PATIENT; PROSTATE TUMOR; PROTEIN EXPRESSION; TUMOR GROWTH;

MUS MUSCULUS;

EID: 31044432108     PISSN: 11107243     EISSN: 11107251     Source Type: Journal    
DOI: 10.1155/JBB.2005.287     Document Type: Article

References (19)

1. Pinto JT, Suffoletto BP, Berzin TM, et al. Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res. 1996;2(9):1445-1451.
2. Heston WD. Characterization and glutamyl preferring carboxypeptidase function of prostate specific membrane antigen: a novel folate hydrolase. Urology. 1997;49(suppl 3A):104-112.
3. Tjoa B, Boynton A, Kenny G, Ragde H, Misrock SL, Murphy G. Presentation of prostate tumor antigens by dendritic cells stimulates T-cell proliferation and cytotoxicity. Prostate. 1996;28(1):65-69.
4. Salgaller ML, Lodge PA, McLean JG, et al. Report of immune monitoring of prostate cancer patients undergoing T-cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen (PSMA). Prostate. 1998;35(2):144-151.
5. Salgaller ML, Tjoa BA, Lodge PA, et al. Dendritic cell-based immunotherapy of prostate cancer. Crit Rev Immunol. 1998;18(1-2):109-119.
6. Tjoa BA, Erickson SJ, Bowes VA, et al. Follow-up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptides. Prostate. 1997;32(4):272-278.
7. Tjoa BA, Simmons SJ, Elgamal A, et al. Follow-up evaluation of a phase II prostate cancer vaccine trial. Prostate. 1999;40(2):125-129.
8. O'Keefe DS, Bacich DJ, Heston WD. Prostate specific membrane antigen. In: Chung LWK, Isaacs WB, Simons JW, eds. Prostate Cancer: Biology, Genetics, and the New Therapeutics. Totowa, NJ: Humana Press; 2001:307-326.
9. Li Y, Tian Z, Rizvi SM, Bander NH, Allen BJ. In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen. Prostate Cancer Prostatic Dis. 2002;5(1):36-46.
10. 213Bi]J591) for radioimmunotherapy of prostate cancer. Cancer Res. 2000;60(21):6095-6100.
11. Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS, Gaudin PB. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res. 1999;59(13):3192- 3198.
12. Guinan P, Shaw M, Mirochnik Y, Slobodskoy L, Ray V, Rubenstein M. Paclitaxel is more effective than thalidomide in inhibiting LNCaP tumor growth in a prostate cancer model. Methods Find Exp Clin Pharmacol. 1998;20(9):739-742.
13. Carter P, Presta L, Gorman CM, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA. 1992;89(10):4285- 4289.
14. Rubenstein M, Mirochnik Y, Chou P, Guinan P. Antisense oligonucleotide intralesional therapy for human PC-3 prostate tumors carried in athymic nude mice. J Surg Oncol. 1996;62(3):194-200.
15. Medical Economics Staff. Physicians' Desk Reference. 56th ed. Montvale, NJ: Medical Economics; 2002:1129-1138.
16. Jordan MA, Wendell K, Gardiner S, Derry WB, Copp H, Wilson L. Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res. 1996;56(4):816-825.
17. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics. CA Cancer J Clin. 2004;54(1):8-29.
18. Joseph IB, Isaacs JT. Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers. Cancer Res. 1997;57(6):1054-1057.
19. Joseph IB, Nelson JB, Denmeade SR, Isaacs JT. Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue. Clin Cancer Res. 1997;3(12 pt 1):2507-2511.